How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,746 results for

Ages and Stages Questionnaire

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Ages and Stages Questionnaire versus the Nipissing Development Screen

Ages and Stages Questionnaire versus the Nipissing Development Screen Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should (...) study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Ages and Stages Questionnaire versus the Nipissing

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Comparative use of the Ages and Stages Questionnaires in the USA and Scandinavia: a systematic review. Full Text available with Trip Pro

Comparative use of the Ages and Stages Questionnaires in the USA and Scandinavia: a systematic review. The aim of this systematic review was to investigate screening practices with the Ages and Stages Questionnaires (ASQ) and the Ages and Stages Questionnaires: Social-Emotional (ASQ:SE) in the USA and Scandinavia and to identify practical lessons and research opportunities.The review was performed for ASQ- and ASQ:SE-related studies in children from birth to 5 years. From nine databases (...) and validation studies are needed throughout Scandinavia. Randomized controlled trials are needed to investigate outcomes in screened versus unscreened cohorts.General and at-risk populations broadly benefited from periodic Ages and Stages Questionnaires (ASQ) and/or Ages and Stages Questionnaires: Social-Emotional (ASQ:SE) screening. Pre-visit ASQ and/or ASQ:SE screenining implementation systems work best. The ASQ and ASQ:SE 'overall' sections are not quantifiable and under-researched.© 2018 Mac Keith Press.

2018 Developmental Medicine and Child Neurology

3. Comparative use of the Ages and Stages Questionnaires in low- and middle-income countries. Full Text available with Trip Pro

Comparative use of the Ages and Stages Questionnaires in low- and middle-income countries. To map the breadth of use of the Ages and Stages Questionnaires (ASQ) in low- and middle-income countries (LMICs) across world regions, and examine procedures for ASQ translation, adaptation, psychometric evaluation, and administration.We conducted a review of all original, peer-reviewed studies written in English referencing use of the ASQ in LMICs. We used a consensus rating procedure to classify each (...) type varied by economy and region.Findings suggest broad global use of the ASQ in a range of countries and cultural and linguistic contexts. There is need for further validation studies across all cited regions and countries and in countries ready to begin to design systems for providing universal developmental screening services.The Ages and Stages Questionnaires (ASQ) has been used in at least 23 low- and middle-income countries (LMICs). The ASQ has been translated into at least 16 languages

2018 Developmental Medicine and Child Neurology

4. Using the ages and stages questionnaire in the general population as a measure for identifying children not at risk of a neurodevelopmental disorder. Full Text available with Trip Pro

Using the ages and stages questionnaire in the general population as a measure for identifying children not at risk of a neurodevelopmental disorder. Early detection of neurodevelopmental disorders (NDDs) enables access to early interventions for children. We assess the Ages and Stages Questionnaire (ASQ)'s ability to identify children with a NDD in population data.Children 4 to 5 years old in the National Longitudinal Survey of Children and Youth (NLSCY) from cycles 5 to 8 were included

2018 BMC Pediatrics

5. Support for the feasibility of the ages and stages questionnaire as a developmental screening tool: a cross-sectional study of South African and Zambian children aged 2-60 months. Full Text available with Trip Pro

Support for the feasibility of the ages and stages questionnaire as a developmental screening tool: a cross-sectional study of South African and Zambian children aged 2-60 months. There is a growing global acknowledgement that improving child survival rates is no longer sufficient. Emphasis is shifting to the improvement of health and developmental trajectories in early childhood. Screening and measurement of these trajectories in low and middle income countries is difficult, however (...) , as they currently rely on developmental tests standardised among populations of children growing up in resource rich environments.This paper presents a comparison of one such tool adapted for use with children living in Southern Africa to children from the United States, Norway, Korea and Spain. The Ages and Stages Questionnaire version 3 (ASQ-3) was adapted and administered to 853 children living in South Africa and Zambia.Children in southern Africa were found to perform significantly better than children

2017 BMC Pediatrics

6. Involving Mothers in Child Development Assessment in a Community-based Participatory Study Using Ages and Stages Questionnaires Full Text available with Trip Pro

Involving Mothers in Child Development Assessment in a Community-based Participatory Study Using Ages and Stages Questionnaires Child-friendly environment project (MAZDAK) is a community-based project for monitoring the development of children in Iran that was implemented as a pilot study in one of the neighborhoods of Tehran (Eyvanak-e Gharb). This study attempted to engage mothers in monitoring of their children's development and assesses the status of children's development by a community (...) -based participatory approach using the ages and stages questionnaires (ASQ).This study was a community-based participatory research. Two hundred households residing in Eyvanak-e Gharb with children under 5-year-old were selected as a convenient sample and completed the ASQ. Descriptive measures were used to describe the overall status of children, in each domain. Furthermore, we compared the current sample with other populations, using independent t-test.This study engaged mothers, trained

2017 International journal of preventive medicine

7. Childhood disability population-based surveillance: Assessment of the Ages and Stages Questionnaire Third Edition and Washington Group on Disability Statistics/UNICEF module on child functioning in a rural setting in South Africa Full Text available with Trip Pro

Childhood disability population-based surveillance: Assessment of the Ages and Stages Questionnaire Third Edition and Washington Group on Disability Statistics/UNICEF module on child functioning in a rural setting in South Africa Epidemiological information on childhood disability provides the basis for a country to plan, implement and manage the provision of health, educational and social services for these vulnerable children. There is, however, currently no population-based surveillance (...) instrument that is compatible with the International Classification of Functioning, Disability and Health (ICF), internationally comparable, methodologically sound and comprehensively researched, to identify children under 5 years of age who are living with disability in South Africa and internationally. We conducted a descriptive pilot study to investigate the sensitivity and specificity of translated versions of the Ages and Stages Questionnaire Third Edition (ASQ-III) and the Washington Group

2016 African journal of disability

8. Evaluation of 1-year-old children development in Isfahan City and its effective factors using ages and stages questionnaire, in 2014 Full Text available with Trip Pro

Evaluation of 1-year-old children development in Isfahan City and its effective factors using ages and stages questionnaire, in 2014 Attention to the development of children as the future generation that leads to the upbringing of productive human resources is an important subject. Development has dimensions that a child should acquire the skills related to them in proper age. Otherwise, he may be affected by developmental delays. There are different factors influencing children's developmental (...) delays and this study is carried out to evaluate the developmental conditions of 1-year-old children in the Isfahan and its effective factors.In a historical cohort, 725 children born in 2013 were selected using multi-stage random sampling from health centers licensed by Isfahan Medical University and followed up to 1-year and their related specifications were extracted from ages and stages questionnaire and their families' files. SPSS 20 software and Pearson and Spearman correlation coefficients

2017 Journal of education and health promotion

9. Developmental Screening in Children with Congenital Heart Disease: Ages and Stages Questionnaires Full Text available with Trip Pro

Developmental Screening in Children with Congenital Heart Disease: Ages and Stages Questionnaires Standardised developmental screening tools are important for the evaluation and management of developmental disorders in children with CHD; however, psychometric properties and clinical utility of screening tools, such as the Ages & Stages Questionnaires, Third Edition (ASQ-3), have not been examined in the CHD population. We hypothesised that the ASQ-3 would be clinically useful (...) for this population. Study design ASQ-3 developmental classifications for 163 children with CHD at 6, 12, 24, and/or 36 months of age were compared with those obtained from concurrent developmental testing with the Bayley Scales of Infant and Toddler Development, Third Edition.When ASQ-3 screening failure was defined as ⩾1 SD below the normative mean, specificity (⩾81.9%) and negative predictive value (⩾81.0%) were high across ASQ-3 areas. Sensitivity was high for gross motor skills (79.6%), increased with age

2017 Cardiology in the young

10. Ages and Stages Questionnaire at 3 Years for Predicting IQ at 5-6 Years. Full Text available with Trip Pro

Ages and Stages Questionnaire at 3 Years for Predicting IQ at 5-6 Years. To assess the predictive value of the 36-month Ages & Stages Questionnaire (ASQ) score for IQ score at age 5 to 6 years in the general population and to identify factors associated with IQ <85 once the ASQ score is taken into account.Data were collected from 939 children enrolled in a population-based prospective cohort study. Developmental outcomes at 36 months were assessed via the ASQ and at 5 to 6 years via

2017 Pediatrics

11. Ages and Stages Questionnaire Social Emotional

Ages and Stages Questionnaire Social Emotional Ages and Stages Questionnaire Social Emotional Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Ages and Stages Questionnaire Social Emotional Ages and Stages Questionnaire Social Emotional Aka: Ages and Stages Questionnaire Social Emotional , ASQ:SE Behavioral Questionnaire , ASQ:SE From Related Chapters II. Indications Behavioral Screening in preschool children III. Description Specific questionnaire for each age of administration: 6, 12, 18, 24, 30, 36, 48 and 60 months Questionnaire addresses 7 areas Self regulation Compliance Communication Adaptive functioning Autonomy Affect

2018 FP Notebook

12. Ages and Stages Questionnaire

Ages and Stages Questionnaire Ages and Stages Questionnaire Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Ages and Stages (...) Questionnaire Ages and Stages Questionnaire Aka: Ages and Stages Questionnaire , ASQ Questionnaire From Related Chapters II. Indications Development screening for age 1 month up to 5.5 years old (19 questionnaires) III. Description Each questionnaire contains 6 questions each in 5 areas (30 questions total) Communication Gross motor Fine motor Problem solving Personal-social Each question asks if the child is performing the given skill Yes: 10 points Sometimes: 5 points Not yet: 0 points Matches well child

2018 FP Notebook

13. A screening questionnaire for convulsive seizures: A three-stage field-validation in rural Bolivia. Full Text available with Trip Pro

A screening questionnaire for convulsive seizures: A three-stage field-validation in rural Bolivia. Epilepsy is one of the most common neurological diseases in Latin American Countries (LAC) and epilepsy associated with convulsive seizures is the most frequent type. Therefore, the detection of convulsive seizures is a priority, but a validated Spanish-language screening tool to detect convulsive seizures is not available. We performed a field validation to evaluate the accuracy of a Spanish (...) -language questionnaire to detect convulsive seizures in rural Bolivia using a three-stage design. The questionnaire was also administered face-to-face, using a two-stage design, to evaluate the difference in accuracy.The study was carried out in the rural communities of the Gran Chaco region. The questionnaire consists of a single screening question directed toward the householders and a confirmatory section administered face-to-face to the index case. Positive subjects underwent a neurological

2017 PLoS ONE

14. Inotersen (Tegsedi) - for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)

of new technology Summary of evidence on comparative efficacy The key evidence to support the use of inotersen in patients with hATTR and polyneuropathy comes from one double-blind, randomised, phase II/III study (NEURO-TTR). Eligible patients were aged 18 to 82 years old and diagnosed with stage 1 (patient is ambulatory) or stage 2 (patient is ambulatory with assistance) hATTR with polyneuropathy. They had a Neuropathy Impairment Score (NIS) of =10 to =130 (range 0 to 244, with higher scores (...) for the components of mNIS+7 and domains of Norfolk QoL-DN composite scores were consistent with the primary outcome analysis, showing benefit in motor, sensory and autonomic neuropathies. In addition, subgroup analyses indicated a consistent treatment effect for both primary outcomes across all subgroups including genotype (V30M versus non-V30M), disease stage (stage 1 versus stage 2), previous treatment with tafamidis or diflunisal (yes versus no), cardiac subpopulation, age (<65 versus =65), gender, race

2019 Scottish Medicines Consortium

15. Patisiran (Onpattro) - the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Patisiran (Onpattro) - the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy. 1 Published 10 June 2019 1 SMC2157 patisiran 2mg/mL concentrate for solution for infusion (Onpattro®) Alnylam Pharmaceuticals 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland (...) . The advice is summarised as follows: ADVICE: following a full submission assessed under the ultra-orphan medicine process patisiran (Onpattro®) is accepted for use within NHSScotland. Indication under review: the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy. In a phase III study of adults with hATTR amyloidosis and polyneuropathy, patisiran was associated with significant improvements compared with placebo

2019 Scottish Medicines Consortium

16. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer

and the experiences, preferences, and values of people with early-stage invasive breast cancer. BACKGROUND Health Condition Breast cancer is a disease in which cells in the breast grow out of control, eventually forming a tumour. Environmental, lifestyle, and genetic factors influence a person’s risk of developing breast cancer. These risk factors may include obesity, physical inactivity, alcohol consumption, age, hormone replacement therapy, dense breasts, genetic mutation, and a personal and/or family history (...) survival rate for breast cancer is about 85%. 5 Most breast cancer cases in Ontario are diagnosed in the early stages, either at stage 1 (43%) or stage 2 (38%). 6 Breast cancer recurrence, which is highest during the second year post-diagnosis, is related to the characteristics of the original breast cancer, such as tumour size, tumour subtype, tumour grade, patient age, and number of affected lymph nodes. 7 The risk of recurrence in another area of the body (distant recurrence) after 5 years

2020 Health Quality Ontario

17. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer P Pertuzumab for adjuvant treatment of ertuzumab for adjuvant treatment of HER2-positiv HER2-positive early stage breast cancer e early stage breast cancer T echnology appraisal guidance Published: 20 March 2019 nice.org.uk/guidance/ta569 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

18. The psychometric properties of the Ages & Stages Questionnaires for ages 2-2.5: a systematic review. Full Text available with Trip Pro

The psychometric properties of the Ages & Stages Questionnaires for ages 2-2.5: a systematic review. Early identification of children with potential development delay is essential to ensure access to care. The Ages & Stages Questionnaires (ASQ) is used as population outcome indicators in England as part of the 2.5-year review.The aim of this article was to systematically review the worldwide evidence for the psychometric properties of the ASQ third edition (ASQ-3TM ) and the Ages & Stages (...) Questionnaires®: Social-Emotional (ASQ:SE). Eight electronic databases and grey literature were searched for original research studies available in English language, which reported reliability, validity or responsiveness of the ASQ-3TM or ASQ:SE for children aged between 2 and 2.5 years. Twenty studies were included. Eligible studies used either the ASQ-3TM or the ASQ:SE and reported at least one measurement property of the ASQ-3TM and/or ASQ:SE. Data were extracted from all papers identified for final

2016 Child: care, health and development

19. Adjuvant Systemic Chemotherapy for Stage II and III Colon Cancer Following Complete Resection

older than 70 years of age in any of three trials that performed this post hoc subgroup analysis [5,6, 8]. These studies have an unclear risk of bias as almost all domains in the Risk of Bias assessment were rated as either low or unclear risk of bias. Caution must be exercised when interpreting post hoc subgroup analyses. Interpretation of Evidence for Stage III Colon Cancer – Recommendations 4 and 5 ? There was agreement among the Working Group members that the overall certainty of the evidence (...) the recommendations as they believed that the toxicities were manageable given the increase in OS. ? The desirable effect (i.e., increased survival) is large. At the same time, the undesirable effects (toxicity) are manageable in this population. The Working Group believed the desirable effect (longer survival) is large relative to the undesirable effects (toxicity) in the selected group of stage III patients. ? The evidence is generalizable to the entire stage III population that is younger than 70 years of age

2019 Cancer Care Ontario

20. Prospective evaluation of the Ages and Stages Questionnaire 3rd Edition in very-low-birthweight infants. (Abstract)

Prospective evaluation of the Ages and Stages Questionnaire 3rd Edition in very-low-birthweight infants. To evaluate the predictive and concurrent diagnostic agreement of the Ages and Stages Questionnaire 3rd Edition (ASQ-3) with the Bayley Scales of Infant and Toddler Development 3rd Edition (Bayley-III) in infants born preterm and very-low-birthweight (PT/VLBW; ≤1250g).We evaluated 141 PT/VLBW infants (68 males, 73 females) born at the KK Women's and Children's Hospital between January 2010 (...) and December 2011, to determine predictive and concurrent diagnostic agreement between the ASQ-3 at 9, 12, 18, and 24 months corrected age and Bayley-III at 24 months. Cut-offs on the ASQ-3 at 24 months were estimated by receiver operating characteristic curves.Sixty (43%) and 25 (18%) failed in any domain of the ASQ-3 and Bayley-III (<70) respectively. A negative predictive value (NPV) >98% was achieved for the motor domain from 9 months, and >90% for the communication domain and the overall results at 24

2016 Developmental Medicine and Child Neurology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>